Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed ...

In a cohort of more than 300 patients with relapsed or refractory disease, 99.1% treated with the CD19/CD22-directed product ...

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute ...

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most ...

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

Chemotherapy and Blinatumomab improve survival rates in common childhood leukemia (B-cell acute lymphoblastic leukemia or B-ALL).